[go: up one dir, main page]

PE20001369A1 - COMBINATION THERAPY FOR HCV BY INDUCTION OF RIBAVIRIN-INTERFERON ALPHA PEGILADO - Google Patents

COMBINATION THERAPY FOR HCV BY INDUCTION OF RIBAVIRIN-INTERFERON ALPHA PEGILADO

Info

Publication number
PE20001369A1
PE20001369A1 PE1999001292A PE00129299A PE20001369A1 PE 20001369 A1 PE20001369 A1 PE 20001369A1 PE 1999001292 A PE1999001292 A PE 1999001292A PE 00129299 A PE00129299 A PE 00129299A PE 20001369 A1 PE20001369 A1 PE 20001369A1
Authority
PE
Peru
Prior art keywords
interferon alpha
pegilado
ribavirin
hcv
induction
Prior art date
Application number
PE1999001292A
Other languages
Spanish (es)
Inventor
Paul W Glue
Janice K Albrecht
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of PE20001369A1 publication Critical patent/PE20001369A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE REFIERE AL USO DE 400 mg/DIA A 1600 mg/DIA DE RIVABIRINA EN ASOCIACION CON 0,5 A 1,5 µg/Kg/POR SEMANA DE INTERFERON ALFA PEGILADO POR DOS PERIODOS DE TRATAMIENTO CARACTERIZADO POR QUE a)EL PRIMER PERIODO ES PARA DISMINUIR SUSTANCIALMENTE LOS NIVELES DEL ARN DETECTABLE; b)EL SEGUNDO PERIODO DE 20 A 30 SEMANAS PARA ERRADICAR EL ARN DEL VHC DETECTABLE POR LO QUE PUEDE SER UTIL PARA EL TRATAMIENTO DE UNA INFECCION CRONICA DE HEPATITIS CREFERS TO THE USE OF 400 mg / DAY TO 1600 mg / DAY OF RIVABIRIN IN ASSOCIATION WITH 0.5 TO 1.5 µg / Kg / WEEK OF INTERFERON ALPHA STICKED FOR TWO PERIODS OF TREATMENT CHARACTERIZED BECAUSE a) THE FIRST PERIOD IS TO SUBSTANTIALLY REDUCE THE LEVELS OF DETECTABLE RNA; b) THE SECOND PERIOD OF 20 TO 30 WEEKS TO ERADICATE DETECTABLE HCV RNA SO IT MAY BE USEFUL FOR THE TREATMENT OF A CHRONIC INFECTION OF HEPATITIS C

PE1999001292A 1998-12-18 1999-12-17 COMBINATION THERAPY FOR HCV BY INDUCTION OF RIBAVIRIN-INTERFERON ALPHA PEGILADO PE20001369A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US21587698A 1998-12-18 1998-12-18

Publications (1)

Publication Number Publication Date
PE20001369A1 true PE20001369A1 (en) 2000-12-09

Family

ID=22804768

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1999001292A PE20001369A1 (en) 1998-12-18 1999-12-17 COMBINATION THERAPY FOR HCV BY INDUCTION OF RIBAVIRIN-INTERFERON ALPHA PEGILADO

Country Status (7)

Country Link
EP (1) EP1140143A2 (en)
JP (1) JP2003507322A (en)
AR (1) AR021876A1 (en)
AU (1) AU2157000A (en)
CA (1) CA2354536A1 (en)
PE (1) PE20001369A1 (en)
WO (1) WO2000037110A2 (en)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
MXPA02011691A (en) 2000-05-26 2004-05-17 Idenix Cayman Ltd Methods and compositions for treating flaviviruses and pestiviruses.
CN100448993C (en) * 2000-06-30 2009-01-07 津莫吉尼蒂克斯公司 Interferon-like protein Zcyto21
US7208167B2 (en) 2000-08-07 2007-04-24 Sciclone Pharmaceuticals, Inc. Treatment of hepatitis C with thymosin and peptide combination therapy
WO2002011749A1 (en) * 2000-08-07 2002-02-14 Sciclone Pharmaceuticals, Inc. Treatment of hepatitis c with thymosin, interferon and ribavirin
BR0114636A (en) * 2000-10-18 2004-02-10 Schering Corp Pegylated interferon-alpha / ribavirin hcv combination therapy
EP1501936B1 (en) 2001-04-20 2008-08-06 ZymoGenetics, Inc. Cytokine protein family
US7910313B2 (en) 2001-04-20 2011-03-22 Zymogenetics, Inc. Cytokine protein family
JP2005504087A (en) 2001-09-28 2005-02-10 イデニクス（ケイマン）リミテツド Methods and compositions for the treatment of hepatitis C virus using 4 'modified nucleosides
CN101172993A (en) 2002-06-28 2008-05-07 埃迪尼克斯(开曼)有限公司 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
JP2005533824A (en) 2002-06-28 2005-11-10 イデニクス（ケイマン）リミテツド 2'-C-methyl-3'-OL-valine ester ribofuranosyl cytidine for the treatment of Flaviviridae infections
MY140819A (en) 2002-06-28 2010-01-29 Idenix Caymans Ltd Modified 2' and 3'-nucleoside prodrugs for treating flaviviridae
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
PL377342A1 (en) 2002-11-15 2006-01-23 Idenix (Cayman) Limited 2'-branched nucleosides and flaviviridae mutation
AU2003300901A1 (en) 2002-12-12 2004-06-30 Idenix (Cayman) Limited Process for the production of 2'-branched nucleosides
PL2604620T5 (en) 2003-05-30 2024-10-14 Gilead Pharmasset Llc Modified fluorinated nucleoside analogues
NZ545159A (en) * 2003-08-13 2009-03-31 Smith Howard J & Ass Pty Ltd Method of treating viral infections
CN101023094B (en) 2004-07-21 2011-05-18 法莫赛特股份有限公司 Preparation of alkyl-substituted 2-deoxy-2-fluoro-d-ribofuranosyl pyrimidines and purines and their derivatives
NZ554442A (en) 2004-09-14 2011-05-27 Pharmasset Inc Preparation of 2'fluoro-2'-alkyl-substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
CN101883590A (en) * 2007-09-14 2010-11-10 先灵公司 Methods of treating patients with hepatitis C
TW200946541A (en) 2008-03-27 2009-11-16 Idenix Pharmaceuticals Inc Solid forms of an anti-HIV phosphoindole compound
EA019341B1 (en) 2008-12-23 2014-02-28 Джилид Фармассет, Ллс. Nucleoside phosphoramidates
EA201100851A1 (en) 2008-12-23 2012-04-30 Фармассет, Инк. NUCLEOSIDE ANALOGUES
US8716263B2 (en) 2008-12-23 2014-05-06 Gilead Pharmasset Llc Synthesis of purine nucleosides
US9198907B2 (en) 2009-04-06 2015-12-01 Ptc Therapeutics, Inc. Combinations of a HCV inhibitor such as bicyclic pyrrole derivatives and a therapeutic agent
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI576352B (en) 2009-05-20 2017-04-01 基利法瑪席特有限責任公司 Nucleoside phosphoramidates
MX2012011171A (en) 2010-03-31 2013-02-01 Gilead Pharmasset Llc Nucleoside phosphoramidates.
JP6069215B2 (en) 2010-11-30 2017-02-01 ギリアド ファーマセット エルエルシー Compound
SG11201400664WA (en) 2011-09-16 2014-04-28 Gilead Pharmassett Llc Methods for treating hcv
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
CA2811250C (en) 2011-10-21 2015-08-11 Abbvie Inc. Methods for treating hcv
SE1450019A1 (en) 2011-10-21 2014-01-10 Abbvie Inc Methods for treating HCV comprising at least two direct-acting antiviral agents, ribavirin but not interferon
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
US20140212491A1 (en) 2013-01-31 2014-07-31 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
EP3038601B1 (en) 2013-08-27 2020-04-08 Gilead Pharmasset LLC Combination formulation of two antiviral compounds
EP3448392A4 (en) 2016-04-28 2020-01-15 Emory University ALCYNE-CONTAINING NUCLEOTIDES AND NUCLEOSIDES THERAPEUTIC COMPOSITIONS AND USES THEREOF

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6387365B1 (en) * 1995-05-19 2002-05-14 Schering Corporation Combination therapy for chronic hepatitis C infection
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
DE69810822T2 (en) * 1997-09-21 2003-11-20 Schering Corp., Kenilworth Combination therapy for the removal of detectable HCV-RNA in patients with chronic hepatitis C infection
ES2172288T3 (en) * 1998-05-15 2002-09-16 Schering Corp COMBINATION THERAPY THAT UNDERSTANDS RIBAVIRINA AND INTERFERED ALPHA IN PATIENTS WHO HAVE NOT BEEN SUBJECTED TO ANTIVIRAL TREATMENT AND HAVE CHRONIC HEPATITIS C INFECTION.

Also Published As

Publication number Publication date
AR021876A1 (en) 2002-08-07
JP2003507322A (en) 2003-02-25
WO2000037110A3 (en) 2000-09-14
AU2157000A (en) 2000-07-12
CA2354536A1 (en) 2000-06-29
EP1140143A2 (en) 2001-10-10
WO2000037110A2 (en) 2000-06-29

Similar Documents

Publication Publication Date Title
PE20001369A1 (en) COMBINATION THERAPY FOR HCV BY INDUCTION OF RIBAVIRIN-INTERFERON ALPHA PEGILADO
PE20000560A1 (en) USE OF PEG-IFN-ALPHA AND RIBAVIRIN FOR THE TREATMENT OF CHRONIC HEPATITIS C
PE119199A1 (en) COMBINATION THERAPY TO ERADICATE DETECTABLE HCV-RNA IN PATIENTS WITH CHRONIC HEPATITIS C INFECTION
PE20001109A1 (en) DERIVATIVES OF RIVABIRIN
MXPA02012443A (en) 3 -PRODRUGS OF 2 -DEOXY-bgr;-L-NUCLEOSIDES.
BR9809425A (en) Alpha interferon-polyethylene glycol conjugates for infection therapy
IT1261949B (en) THERAPEUTIC COMPOSITION BASED ON HUMAN INTERFERONE, USE OF HUMAN INTERFERONE IN SUCH COMPOSITION AND RELATED METHOD.
NZ307089A (en) Alpha substituted pyrimidine thioalkyl and alkylether compounds and medicaments
MX9202374A (en) 1,3-OXATIOLANES USEFUL IN THE TREATMENT OF HEPATITIS.
EA200701386A1 (en) POLYALKYLENE GLYCOL WITH RESIDUAL FOR CONJUGATION OF BIOLOGICALLY ACTIVE CONNECTION
BR0013771A (en) Compound, methods of treating a viral infection in a mammal, inhibiting hiv reverse transcriptase, and preventing hiv infection or treating hiv infection, use of a compound, and, pharmaceutical composition
CO5251404A1 (en) AZALIDA ANTIBIOTIC COMPOUNDS
PE20010284A1 (en) THE USE OF AN ANTIOXIDANT WITH RIBAVIRIN TO PREPARE A MEDICATION FOR THE TREATMENT OF A VIRAL INFECTION
ES2192101T3 (en) CRYSTAL FORMS OF ETO2C-CH2- (R) CGL-AZE-PAB-OH.
ES2157252T3 (en) APPLICATION OF RILUZOL IN THE TREATMENT OF NEURO-AIDS.
BR0306820A (en) Use of cox-2 inhibitors in combination with antiviral agents for the treatment of papillomavirus infections.
PE20001386A1 (en) COMBINATION THERAPY FOR HCV BY INDUCTION OF RIBAVIRIN-INTERFERON ALPHA
BR0016831A (en) Therapeutic composition and contact lens impregnated by it
AP2002002652A0 (en) The use of azalide antibiotic composition for treating or preventing a bacterial or protozoal infection in mammals.
PE20010490A1 (en) MOFETILE MYCOPHENOLATE IN ASSOCIATION WITH PEG-IFN-ALPHA
IT1264965B1 (en) USE OF ALFA 1-BLOCCANTI IN THE TREATMENT OF EARLY EJACULATION
PE61699A1 (en) PHARMACEUTICAL COMPOSITION OF LAMIVUDINE
FI973184A7 (en) Combination therapy for HIV infection using the HIV protease inhibitor indinavir and the reverse transcriptase inhibitor 3TC, possibly in combination with AZT, DDI, or DDC
WO1999051256A3 (en) Use of l-glu-l-trp in the treatment of hiv infection
AP2049A (en) Medicament containing activated antithrombin III

Legal Events

Date Code Title Description
FC Refusal